NATICK, Mass.--(BUSINESS WIRE)--Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced the commercial availability of its comprehensive Virtual Care Suite (VCS) in the United States.

马萨诸塞州纳蒂克市。-（商业新闻短讯）--致力于消除肥胖的Allurion Technologies，Inc.（纽约证券交易所：ALUR）今天宣布其综合虚拟护理套件（VCS）在美国上市。

Already in use by thousands of providers in over 50 countries, the VCS is a dynamic weight-loss management suite powered by artificial intelligence (AI) featuring remote patient monitoring, telehealth and care team collaboration all under the one digital umbrella, designed to maximize patient outcomes and satisfaction.

VCS是一个由人工智能（AI）提供支持的动态减肥管理套件，已在50多个国家的数千家供应商中使用，其功能是在一个数字保护伞下进行远程患者监测，远程医疗和护理团队协作，旨在最大程度地提高患者的疗效和满意度。

In 2023, Allurion added Coach Iris, a 24/7 AI-powered weight loss coach, to the VCS, enabling automated, conversational coaching and a more personalized behavior change program tailored to patient needs..

2023年，Allurion将Coach Iris（一位全天候人工智能减肥教练）加入到风投中，实现了自动化、对话式辅导，并根据患者需求制定了更个性化的行为改变计划。。

“After witnessing the profound impact our technology has had globally, we are thrilled to launch the VCS in the United States. Our team is incredibly excited to provide US clinics with digital solutions to help them significantly bolster both clinical outcomes and patient experience for all weight-loss treatments, including anti-obesity medications and bariatric surgery, especially as GLP-1 usage surges,” said Brian Conyer, Vice President of Digital Health.

数字健康副总裁布莱恩·康耶（BrianConyer）表示：“在见证了我们的技术在全球范围内产生的深远影响之后，我们很高兴在美国推出VCS。我们的团队为我们的诊所提供数字解决方案，帮助他们显着提高所有减肥治疗的临床效果和患者体验，包括抗肥胖药物和减肥手术，尤其是在GLP-1使用激增的情况下。”。

“Our research indicates that the VCS has already enhanced patient results, engagement, and satisfaction. Clinics with the highest VCS usage achieve an additional 11% weight loss1, with 16% more patients reaching their goals1, and a 17% increase in Net Promoter Score (NPS)2.”.

“我们的研究表明，VCS已经提高了患者的效果，参与度和满意度。VCS使用率最高的诊所体重减轻了11%，达到目标的患者增加了16%，净启动子评分（NPS）增加了17%。”2。

The VCS will be presented for the first time in the United States at the Obesity Medicine Conference in Denver on April 25, where providers will have the opportunity to request 1:1 meetings to discover the solution. As part of the launch, Allurion will also be unveiling a new version of Allurion Insights, the web-based dashboard that providers use to navigate the VCS..

这些风投将于4月25日在丹佛举行的肥胖医学会议上首次在美国亮相，届时提供者将有机会要求1:1的会议来发现解决方案。作为此次发布的一部分，Allurion还将推出新版本的Allurion Insights，这是一个基于网络的仪表板，提供商用于导航风投。。

The new version of Allurion Insights includes:

新版Allurion Insights包括：

Responsive, mobile app-like design: for providers and care teams on the move who want to stay in sync with their patients on their mobile phones

响应迅速、类似移动应用程序的设计：适用于移动中希望通过手机与患者保持同步的提供商和护理团队

More efficient navigation: thoughtfully organized by user activities, the updated navigation experience is designed to create more seamless access to a number of different data streams for individual patients

更高效的导航：通过用户活动精心组织，更新的导航体验旨在为个别患者创建对多个不同数据流的无缝访问

Multitasking: for busy providers, multitasking allows them to document a clinical note or launch a video consultation while seamlessly viewing other patient information

多任务处理：对于繁忙的提供者来说，多任务处理允许他们记录临床记录或启动视频咨询，同时无缝地查看其他患者信息

“As use of anti-obesity medication in the United States increases, providers are being challenged to offer close follow-up and lifestyle modification coaching at scale,” said Shantanu Gaur, Founder and CEO. “We are thrilled to make the VCS available in the US and believe it could become an integral part of practices offering weight loss therapy of any kind.”.

创始人兼首席执行官Shantanu Gaur说：“随着美国抗肥胖药物的使用增加，提供者面临的挑战是提供大规模的密切随访和改变生活方式的指导。”。“我们很高兴能在美国推出这些风投，相信它可以成为提供任何减肥疗法的实践中不可或缺的一部分。”。

Sources: 1. Allurion Internal PEX Report, March 2023; 2. Allurion Internal Business Excellence Analysis, Q4 2023

资料来源：1。Allurion内部PEX报告，2023年3月；2、Allurion内部卓越业务分析，2023年第4季度

About Allurion

关于Allurion

Allurion is dedicated to ending obesity. The Allurion Program is a weight loss platform that features the Allurion Gastric Balloon, the world’s first and only swallowable, procedure-less intragastric balloon for weight loss, and offers access to the Allurion Virtual Care Suite, including the Allurion Mobile App for consumers, Allurion Insights for health care providers featuring the Coach Iris AI Platform, and the Allurion Connected Scale.

Allurion致力于消除肥胖。Allurion计划是一个减肥平台，其特点是Allurion胃气球，这是世界上第一个也是唯一一个可吞咽的，无程序的胃内气球减肥，并提供对Allurion虚拟护理套件的访问，包括面向消费者的Allurion移动应用程序，以Coach Iris AI平台为特色的Allurion Insights医疗保健提供商以及Allurion Connected Scale。

The Allurion Virtual Care Suite is also available to providers separately from the Allurion Program to help customize, monitor and manage weight loss therapy for patients regardless of their treatment plan: gastric balloon, surgical, medical or nutritional. The Allurion Gastric Balloon is an investigational device in the United States..

Allurion虚拟护理套件也可与Allurion计划分开提供，以帮助定制，监测和管理患者的减肥治疗，无论其治疗计划如何：胃球囊，手术，医疗或营养。Allurion胃气球是美国的一种研究设备。。

For more information about Allurion and the Allurion Virtual Care Suite, please visit www.allurion.com

有关Allurion和Allurion虚拟护理套件的更多信息，请访问www.Allurion.com

Allurion is a trademark of Allurion Technologies, Inc. in the United States and countries around the world.

Allurion是Allurion Technologies，Inc.在美国和世界各国的商标。

Forward-Looking Statements

前瞻性声明

This press release may contain certain forward-looking statements within the meaning of the U.S. federal and state securities laws. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions and include statements regarding Allurion’s expectations for, and market acceptance of, Allurion’s Virtual Care Suite and the Allurion Program in general, Allurion’s ability to scale its business and in particular for the VCS, and the ability of the VCS to improve clinical and patient outcomes.

本新闻稿可能包含美国联邦和州证券法所指的某些前瞻性声明。这些前瞻性陈述通常由“相信”，“项目”，“期望”，“预期”，“估计”，“打算”，“战略”，“未来”，“机会”，“计划”，“可能”，“应该”，“将会”，“将会”，“将会”，“将继续”，“将可能产生”和类似的表达来识别，包括关于Allurion对Allurion虚拟护理套件和Allurion计划的期望和市场接受程度的陈述，以及Allurion扩大其业务规模的能力，特别是对风投公司的能力，以及风投公司改善临床和患者结果的能力。

Forward-looking statements are predictions, projections and other statements about future events that reflect the current beliefs and assumptions of Allurion’s management based on information currently available to them and, as a result, are subject to risks and uncertainties. Many factors could cause actual future results or developments to differ materially from the forward-looking statements in this communication, including but not limited to (i) the ability of Allurion to obtain and maintain regulatory approvals for and successfully commercialize the Allurion Program, including the Allurion Balloon and the VCS, (ii) the timing of, and results from, our clinical studies and trials, (iii) the evolution of the markets in which Allurion competes, (iv) the ability of Allurion to defend its intellectual property, (v) the impact of the COVID-19 pandemic, the Russia and Ukraine war, and the Israel-Hamas conflict on Allurion’s business, (vi) Allurion’s expectations regarding its market opportunities, including those for the VCS platform, and (vii) the risk of economic .

前瞻性陈述是关于未来事件的预测、预测和其他陈述，反映了Allurion管理层基于当前可用信息的当前信念和假设，因此存在风险和不确定性。许多因素可能导致未来的实际结果或发展与本通讯中的前瞻性陈述存在重大差异，包括但不限于（i）Allurion获得和维持监管部门批准并成功商业化Allurion计划（包括Allurion气球和风投）的能力，（ii）我们的临床研究和试验的时间和结果，（iii）Allurion竞争市场的演变，（iv）Allurion捍卫其知识产权的能力，（v）新型冠状病毒疫情、俄罗斯和乌克兰战争以及以色列-哈马斯冲突对Allurion业务的影响，（vi）Allurion对其市场机会，包括风险投资平台的市场机会，以及（vii）经济风险。